Literature DB >> 24865876

Which quality of life instruments are preferred by cancer patients in Japan? Comparison of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and the Functional Assessment of Cancer Therapy-General.

Kazuki Sato1, Megumi Shimizu, Mitsunori Miyashita.   

Abstract

PURPOSE: We compared two health-related quality of life (HRQOL) instruments used for cancer patients [the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G)] to identify which instrument cancer patients most preferred.
METHODS: Adult cancer patients who had received cancer treatments within the previous 2 years (n = 395) completed both surveys; participants assessed the importance, necessity, and appropriateness of each as an indicator of their quality of life.
RESULTS: The patients significantly preferred the FACT-G over the EORTC QLQ-C30 as a more important (effect size (ES) = 0.37, P < 0.001), necessary (ES = 0.18, P < 0.001), and appropriate questionnaire (ES = 0.14, P = 0.005). The subgroups of patients with good performance status, and those who reported low levels of work disruption, significantly preferred the FACT-G more than the other. The corresponding correlation coefficients were the following: physical functioning and well-being subscale, r = 0.65; emotional functioning and well-being subscale, r = 0.60; social functioning and social/family well-being subscale, r = 0.00; and role functioning and functional well-being subscale, r = 0.41.
CONCLUSIONS: We recommend using the FACT-G if the performance status of the subject is good, e.g., in outpatient or cancer survivor surveys, based on the observed patient preferences. When performance status is not good, an instrument should be chosen after considering the differences between their scale structures and social domains and based on the availability of disease-specific modules.

Entities:  

Mesh:

Year:  2014        PMID: 24865876     DOI: 10.1007/s00520-014-2287-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  14 in total

1.  A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

Authors:  K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

2.  The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care.

Authors:  Mogens Groenvold; Morten Aa Petersen; Neil K Aaronson; Juan I Arraras; Jane M Blazeby; Andrew Bottomley; Peter M Fayers; Alexander de Graeff; Eva Hammerlid; Stein Kaasa; Mirjam A G Sprangers; Jakob B Bjorner
Journal:  Eur J Cancer       Date:  2005-09-12       Impact factor: 9.162

Review 3.  Prevalence of pain in patients with cancer: a systematic review of the past 40 years.

Authors:  M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn
Journal:  Ann Oncol       Date:  2007-03-12       Impact factor: 32.976

4.  Trajectory of performance status and symptom scores for patients with cancer during the last six months of life.

Authors:  Hsien Seow; Lisa Barbera; Rinku Sutradhar; Doris Howell; Deborah Dudgeon; Clare Atzema; Ying Liu; Amna Husain; Jonathan Sussman; Craig Earle
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

5.  Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice.

Authors:  Claire F Snyder; Sydney M Dy; Danetta E Hendricks; Julie R Brahmer; Michael A Carducci; Antonio C Wolff; Albert W Wu
Journal:  Support Care Cancer       Date:  2007-02-21       Impact factor: 3.603

6.  Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese.

Authors:  H Fumimoto; K Kobayashi; C H Chang; S Eremenco; Y Fujiki; S Uemura; Y Ohashi; S Kudoh
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

Review 7.  Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G.

Authors:  Madeleine T King; Martin R Stockler; David F Cella; David Osoba; David T Eton; Joanna Thompson; Amy R Eisenstein
Journal:  J Clin Epidemiol       Date:  2009-08-27       Impact factor: 6.437

8.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

9.  Preliminary results of the generation of a shortened quality-of-life assessment for patients with advanced cancer: the FACIT-Pal-14.

Authors:  Liang Zeng; Gillian Bedard; David Cella; Nemica Thavarajah; Emily Chen; Liying Zhang; Margaret Bennett; Kenneth Peckham; Sandra De Costa; Jennifer L Beaumont; May Tsao; Cyril Danjoux; Elizabeth Barnes; Arjun Sahgal; Edward Chow
Journal:  J Palliat Med       Date:  2013-04-16       Impact factor: 2.947

10.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

View more
  1 in total

Review 1.  Incorporating Quality of Life Metrics in Interventional Oncology Practice.

Authors:  David Li; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.